178 related articles for article (PubMed ID: 27092678)
1. [Hydroxychloroquine for autoimmune diseases].
Danza Á; Graña D; Goñi M; Vargas A; Ruiz-Irastorza G
Rev Med Chil; 2016 Feb; 144(2):232-40. PubMed ID: 27092678
[TBL] [Abstract][Full Text] [Related]
2. Hydroxychloroquine in rheumatic autoimmune disorders and beyond.
Nirk EL; Reggiori F; Mauthe M
EMBO Mol Med; 2020 Aug; 12(8):e12476. PubMed ID: 32715647
[TBL] [Abstract][Full Text] [Related]
3. Retinal toxicity associated with chronic exposure to hydroxychloroquine and its ocular screening. Review.
Geamănu Pancă A; Popa-Cherecheanu A; Marinescu B; Geamănu CD; Voinea LM
J Med Life; 2014 Sep; 7(3):322-6. PubMed ID: 25408748
[TBL] [Abstract][Full Text] [Related]
4. New use for an old treatment: Hydroxychloroquine as a potential treatment for systemic vasculitis.
Casian A; Sangle SR; D'Cruz DP
Autoimmun Rev; 2018 Jul; 17(7):660-664. PubMed ID: 29729450
[TBL] [Abstract][Full Text] [Related]
5. Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy.
Abarientos C; Sperber K; Shapiro DL; Aronow WS; Chao CP; Ash JY
Expert Opin Drug Saf; 2011 Sep; 10(5):705-14. PubMed ID: 21417950
[TBL] [Abstract][Full Text] [Related]
6. Hydroxychloroquine: a multifaceted treatment in lupus.
Costedoat-Chalumeau N; Dunogué B; Morel N; Le Guern V; Guettrot-Imbert G
Presse Med; 2014 Jun; 43(6 Pt 2):e167-80. PubMed ID: 24855048
[TBL] [Abstract][Full Text] [Related]
7. [Hydroxychloroquine and systemic lupus: a reappraisal].
Costedoat-Chalumeau N; Leroux G; Amoura Z; Piette JC
Rev Med Interne; 2008 Sep; 29(9):735-7. PubMed ID: 17618016
[TBL] [Abstract][Full Text] [Related]
8. Hydroxychloroquine dosing in immune-mediated diseases: implications for patient safety.
Gianfrancesco MA; Schmajuk G; Haserodt S; Trupin L; Izadi Z; Jafri K; Shiboski S; Sirota M; Dudley RA; Yazdany J
Rheumatol Int; 2017 Oct; 37(10):1611-1618. PubMed ID: 28748425
[TBL] [Abstract][Full Text] [Related]
9. Hydroxychloroquine reduces microglial activity and attenuates experimental autoimmune encephalomyelitis.
Koch MW; Zabad R; Giuliani F; Hader W; Lewkonia R; Metz L; Wee Yong V
J Neurol Sci; 2015 Nov; 358(1-2):131-7. PubMed ID: 26344560
[TBL] [Abstract][Full Text] [Related]
10. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus.
Akhavan PS; Su J; Lou W; Gladman DD; Urowitz MB; Fortin PR
J Rheumatol; 2013 Jun; 40(6):831-41. PubMed ID: 23588942
[TBL] [Abstract][Full Text] [Related]
11. Detection of Hydroxychloroquine Retinal Toxicity by Automated Perimetry in 60 Rheumatoid Arthritis Patients with Normal Fundoscopic Findings.
Motarjemizadeh Q; Aidenloo NS; Abbaszadeh M
Glob J Health Sci; 2015 Jun; 8(3):59-64. PubMed ID: 26493438
[TBL] [Abstract][Full Text] [Related]
12. The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review.
Wallace DJ
Lupus; 1996 Jun; 5 Suppl 1():S59-64. PubMed ID: 8803913
[TBL] [Abstract][Full Text] [Related]
13. Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial.
Hartman O; Kovanen PT; Lehtonen J; Eklund KK; Sinisalo J
Eur Heart J Cardiovasc Pharmacother; 2017 Apr; 3(2):92-97. PubMed ID: 28025216
[TBL] [Abstract][Full Text] [Related]
14. Early effect of hydroxychloroquine therapy: relationship between cumulative dose and retinal thickness.
Agarwal P; Wong YH; Dasgupta E; Agarwal R; Livingstone BI; Ramamurthy S; Chyn GS
Cutan Ocul Toxicol; 2015; 34(3):179-84. PubMed ID: 25068998
[TBL] [Abstract][Full Text] [Related]
15. Discontinuation of antimalarial drugs in systemic lupus erythematosus.
Wang C; Fortin PR; Li Y; Panaritis T; Gans M; Esdaile JM
J Rheumatol; 1999 Apr; 26(4):808-15. PubMed ID: 10229401
[TBL] [Abstract][Full Text] [Related]
16. A descriptive study of the factors associated with damage in Malaysian patients with lupus nephritis.
Shaharir SS; Ghafor AH; Said MS; Kong NC
Lupus; 2014 Apr; 23(4):436-42. PubMed ID: 24399814
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulators in SLE: Clinical evidence and immunologic actions.
Durcan L; Petri M
J Autoimmun; 2016 Nov; 74():73-84. PubMed ID: 27371107
[TBL] [Abstract][Full Text] [Related]
18. Experience with the use of hydroxychloroquine for the treatment of lupus erythematosus.
Momose Y; Arai S; Eto H; Kishimoto M; Okada M
J Dermatol; 2013 Feb; 40(2):94-7. PubMed ID: 23216212
[TBL] [Abstract][Full Text] [Related]
19. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature.
Costedoat-Chalumeau N; Amoura Z; Huong DL; Lechat P; Piette JC
Autoimmun Rev; 2005 Feb; 4(2):111-5. PubMed ID: 15722258
[TBL] [Abstract][Full Text] [Related]
20. Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study.
Jallouli M; Francès C; Piette JC; Huong du LT; Moguelet P; Factor C; Zahr N; Miyara M; Saadoun D; Mathian A; Haroche J; De Gennes C; Leroux G; Chapelon C; Wechsler B; Cacoub P; Amoura Z; Costedoat-Chalumeau N;
JAMA Dermatol; 2013 Aug; 149(8):935-40. PubMed ID: 23824340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
